Studies in cervical and ovarian cancers revealed that activation of the PI3K/Akt/mTOR pathway is associated with resistance to microtubule-targeting agents, implicating a potential benefit of combined targeting of both the microtubules and the PI3K/Akt/mTOR pathway [18, 31]. The gene discussed is AKT1; the disease is ovarian carcinoma.